TERRAIN: A randomized, double-blind, phase II study comparing MDV3100 with bicalutamide (Bic) in men with metastatic castrate-resistant prostate cancer (CRPC).
Edwina S. Baskin-Bey
Employment or Leadership Position - Astellas Pharma
Neal D. Shore
Consultant or Advisory Role - Medivation/Astellas Pharma
Kenya Barber
Employment or Leadership Position - Astellas Pharma
Taoufik Ouatas
Employment or Leadership Position - Astellas Pharma (U)
Research Funding - Astellas Pharma
Axel Heidenreich
Consultant or Advisory Role - Astellas Pharma; Ipsen; Janssen-Cilag; Sanofi ; Takeda
Honoraria - Amgen; Astellas Pharma; Bayer; GlaxoSmithKline; Ipsen; Janssen-Cilag; Pfizer; Sanofi ; Takeda